Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Lupus Research Institute Awards $3.6 Million for Bold Novel Research Driving to New Treatments and a Cure

Visionary Science Holds Promise for Solving Lupus and Other Autoimmune Diseases


News provided by

Lupus Research Institute

Jan 31, 2013, 01:18 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) - world's leading supporter of innovative research in lupus -- today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years.  In just its first decade of service, the LRI has awarded more than $40 million for novel research with documented discoveries that are among the most pivotal in lupus.

12 Innovative Scientific Directions
Tackling the complexities of lupus from bold out-of-the-box perspectives, the new studies look at several potential targets for developing new drug treatments, reasons why the immune system turns against the lupus patient's own cells and organs, and new treatment approaches to correct these immune system defects.  The new awards also deal with serious complications of lupus, including blood clots and damage to the kidney and the central nervous system. The 12 grant recipients were selected from nearly 100 applications through a rigorous review process by the Institute's scientific advisors and 70 lupus experts nationwide.

"Entirely original as well as highly promising, each of these studies exemplifies the investment in innovation that sets the Lupus Research Institute apart," said Margaret Dowd, LRI President and CEO. "Our novel research strategy over the past decade has taken scientific discovery in lupus to an unprecedented level of success - producing breakthroughs that are driving new treatments. LRI investigators are increasingly picking up the pace, moving studies from the lab to the human disease and to the clinic, keeping lupus patients healthier and safer while we drive to a cure."

"The Lupus Research Institute is unique in its ability to set the process of discovery in motion," noted world-leading immunologist Dr. William Paul, LRI Scientific Advisory Board Chairman and National Academy of Sciences member. "By identifying and funding visionary work, the LRI sparks a chain of path-breaking scientific achievements that have the potential to point the way to new therapies for lupus and autoimmune disease."

Why Does the Immune System Turn Against the Body and How Can We Stop It?
Nine of the LRI-funded investigators are seeking to understand why in some people the immune system, which normally protects, turns and begins to attack the body. This new insight promises to pave the way for more effective and safer treatments for autoimmune disease that prevent the immune system from attacking the body while leaving it able to fight infection.

Can We Reduce Virus-Fighters that Drive Lupus?
Viral infections trigger the immune system to make large amounts of virus-fighting proteins known as interferons. But too much interferon may cause the immune system to attack the body in lupus. Two new studies will take different approaches to find out how production of interferons might be lessened as a way to treat lupus.

"Having discovered how a particular protein can limit the amount of interferon produced by cells, we are trying to use this natural means of controlling the amount of interferon produced." 
Xiaoyo Hu, MD, PhD, Hospital for Special Surgery, NY, NY

"In chronic viral infections such as HIV, interferon production eventually declines, whereas in lupus and some other autoimmune diseases it does not. We are asking how viruses diminish interferon production. Our research could lead to new treatment approaches to turn off interferon in lupus and other autoimmune diseases."   
Elina Zuniga, PhD, University of California, San Diego, CA

Which Interferon is the Right Target for Treatments?
"Several treatments that target interferons are in development for lupus. Our team is examining an unusual interferon - interferon kappa - to see if it has harmful or beneficial effects and if it should be targeted in therapies."
Deborah Lenschow, MD, PhD, Washington University in St. Louis, MO

Why Women?
"Nine out of 10 people with lupus are women. We are testing how female sex hormones might activate the immune response and initiate autoimmunity. Our work could identify new drug targets in lupus."
Stefania Gallucci, MD, Temple University, School of Medicine, Philadelphia, PA

Are Germs to Blame?
"We are applying the most cutting edge technologies to search for evidence that germs in our gut serve as triggers for lupus. Our studies may lead to new approaches for early diagnosis and therapeutic intervention."
Gregg Silverman, MD, New York University, NY, NY

How Does Lupus Develop?
"We are looking at why people with alterations in a family of little-known proteins found on immune cells are at risk for lupus and other autoimmune diseases. These proteins may be potential new drug targets in diseases of the immune system and lupus." 
Randall Davis, MD, University of Alabama at Birmingham, AL

Are Defective Proteins the Culprit?
"Our work will establish how a specific protein, ABIN-1, inside immune cells might explain why some people are at risk for lupus, and if so might offer a new target for a drug treatment."
Averil Ma, MD, The University of California, San Francisco, CA

Could Blocking One Rare Cell Provide a Priceless Treatment Approach?
"We are the first group to look at whether a rare and unusual B cell linked to lupus is actually contributing to the disease. If so, these cells could be blocked to treat the disease and/or tracked to aid diagnosis."
Roberta Pelanda, PhD, National Jewish Health, Denver, CO

Can More Immune Cells Help?
"We are exploring a new approach to treating lupus by boosting the numbers of specialized immune cells that stop unwanted immune responses."
Joe Larkin, PhD, University of Florida, Gainesville, FL

How Can We Better Treat Common Complications of Lupus?
Three investigators are exploring new ideas on how to predict, prevent and treat some of the most devastating complications of lupus.

Can a Food Supplement Prevent Blood Clots?
"Blood clots triggered by autoantibodies are a major complication of lupus. We are looking at how blood clots form in lupus and testing if a natural chemical found in certain foods, rutin, may be able to prevent clots. If so, we will quickly start testing rutin in humans since it is already approved as a food supplement by the FDA."
Bruce Furie, MD, Beth Israel Deaconess Medical Center, MA

Is There a Way to Prevent Lupus Kidney Damage?
"We are investigating whether a type of protein found on the surface on kidney cells worsens the kidney damage caused by lupus antibodies and whether release of these proteins could be blocked to prevent lupus kidney damage."
Jane Salmon, MD, Hospital for Special Surgery, NY, NY 

How Can We Diagnose Lupus in the Brain?
"We are applying the state-of-the-art technology in a comprehensive search for biomarkers that can improve the diagnosis and treatment of lupus in the central nervous system."  
Chandra Mohan, MD, PHD, University of Texas Southwestern Medical Center, Dallas, TX

About Lupus
A complex autoimmune disease, lupus affects over 1.5-million Americans, primarily women.

About The Lupus Research Institute
The Lupus Research Institute (LRI), the world's leading private supporter of innovative research, pioneers discovery and champions scientific creativity to find solutions to lupus.

SOURCE Lupus Research Institute

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.